Novartis reports sustained efficacy of Rhapsido in chronic urticaria with benefits maintained through 52 weeks

Novartis reported 52-week Phase III results showing Rhapsido (remibrutinib) sustained efficacy in chronic inducible urticaria (CIndU). The drug improved symptoms in symptomatic dermographism, cold urticaria, and cholinergic urticaria. Response rates at Week 52 were 46.8%, 83.3%, and 58.2% respectively. Safety profile remained consistent with prior studies. Novartis aims to expand Rhapsido's availability.

Original reporting
Published Nov 14, 2026, 1:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 15, 2026, 11:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$NVS
Bullish
high confidence
Mentioned
$NVS
Relevance
8/10
AlphAI data visualization · based on indianpharmapost.com
Decision brief

The 30-second read

$NVSBullishMed
01

Why it matters

The 52‑week data provide the most extensive efficacy evidence to date, supporting potential label expansion and future market uptake.

02

Market read

First comprehensive long‑term trial results for a novel urticaria therapy, likely to influence Novartis' stock and sector sentiment.

03

What to watch

Regulatory timelines and reimbursement negotiations could delay commercial impact despite strong data.

Relevance 8/10Novelty 8/10Timing: today

Background

Novartis' Rhapsido (remibrutinib) is an oral BTK inhibitor targeting chronic inducible urticaria, a niche but unmet therapeutic area.

Company-level read

Ticker impact

$NVSBullishHigh confidence
Context

Novartis reported new 52‑week Phase III data for Rhapsido in chronic inducible urticaria, showing sustained efficacy and safety.

Expected impact

likely upward pressure as market prices in the favorable efficacy data.

Evidence & confidence

First disclosure of comprehensive 52‑week outcomes; data are material for a large pharma and could influence upcoming regulatory filings.

Market effects

Strengthens the immunology/dermatology segment and may lift peer biotech stocks developing BTK inhibitors.

European and US markets could see modest gains in pharma indices.

Adds to global biotech pipeline confidence, potentially influencing investor sentiment worldwide.

Counterpoint

If the market has already priced in a positive outlook for Novartis' immunology franchise, the data may be already reflected.

Key entities

  • Novartis

    Swiss multinational pharmaceutical company developing Rhapsido.

  • Rhapsido (remibrutinib)

    Oral BTK inhibitor for chronic inducible urticaria.

Related articles

$NVSMed

Novartis CEO Warns US-China Biotech Curbs

Novartis CEO Vas Narasimhan warned on Bloomberg TV that US-China biotech curbs could limit technology exchange, hindering R&D and market access. The Treasury Department proposed including biotech in investment limits for foreign adversaries, affecting multinational drugmakers like Novartis. Restrictions may slow drug development and access to key markets.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$NVSMedAI 8/10

Novartis Trims Growth Target at Annual Management Day, Shares Slide

Novartis reduced its mid-term sales growth outlook to 5% annually from 2026-2031, down from a prior 5-6% range. Shares fell 3% on the news. The revision follows patent expirations and clinical trial failures, including a $2.2B writedown. Despite this, Novartis raised peak sales forecasts for three key drugs: Kesimpta, Scemblix, and Leqvio. The company expects growth beyond 2031 from internally developed medicines, with 10 in late-stage development.

$NVSMed

Novartis trims medium-term growth target, shares fall

Novartis reduced its annual sales growth target to 5% through 2031, down from a previous range of 5%-6%. Shares fell 3.3% after the announcement, which came amid patent expirations and clinical trial setbacks. The company expects growth from existing drugs like Kesimpta, Scemblix, and Leqvio, with no large acquisitions planned. Analysts anticipate growth slowing post-2030 due to competition for key drugs.